Last updated: July 27, 2025
Introduction
The pharmaceutical sector continually evolves, driven by innovation, regulatory shifts, and market dynamics. For stakeholders interested in NDC 72205-0107, understanding its market landscape and price trajectory is vital for informed decision-making. This article offers a comprehensive analysis of the drug’s current market position and projects future pricing trends based on available data, competitive landscape, and regulatory factors.
Overview of NDC 72205-0107
The National Drug Code (NDC) 72205-0107 references Avasimibe, an experimental lipid-lowering agent primarily investigated for metabolic and cardiovascular disorders. Although not widely marketed presently, its development trajectory influences its valuation and market prospects.
Development Status
Avasimibe was developed by Desano Pharmaceuticals, primarily targeted for atherosclerosis management. However, clinical trials revealed safety concerns and limited efficacy, leading to its discontinuation in early-stage trials for some indications [1]. Despite this, certain formulations and derivatives of avasimibe still hold investigational value in niche clinical trials, contributing to a niche market segment.
Market Landscape
Current Market Environment
- Market Presence: As of 2023, NDC 72205-0107 is not associated with marketed drugs in major therapeutic categories. Its primary association remains within the investigational framework, limiting supply and demand metrics.
- Competitor Drugs: Lipid-lowering therapies like statins (e.g., atorvastatin, rosuvastatin), PCSK9 inhibitors (e.g., evolocumab), and new agents such as bempedoic acid dominate the market landscape.
- Market Needs: The unmet need for novel lipid modulators persists, especially in patients intolerant to statins. This gap provides potential for innovative agents like avasimibe derivatives.
Regulatory and Patent Status
- Patent Expiry & Exclusivity: No granted patents for commercial avasimibe formulations currently limit market exclusivity. Any future developments depend on patent applications and regulatory approvals.
- Regulatory Pathways: Since initial trials were discontinued, pursuing accelerated approval pathways would require promising new efficacy data, which presently does not exist.
Market Drivers & Barriers
- Drivers: Growing awareness of residual cardiovascular risk, expanding lipid management guidelines, and expanding indications for alternative lipid therapies.
- Barriers: Prior safety concerns, competition from established agents, and a limited clinical pipeline diminish market penetration prospects.
Price Analysis
Historical Pricing Trends
- Research-Grade Avasimibe: In early development stages, research supply prices hovered around $1,000-$2,000 per gram, highly dependent on bulk procurement and regulatory status [2].
- Clinical Trial Supply: Typically priced higher, with costs ranging from $5,000 to $10,000 per kilogram, driven by manufacturing complexity and regulatory oversight.
Projected Market Pricing
Given the current status and lack of marketed formulations:
- Potential Launch Price: If avasimibe or derivatives were to re-enter the market post-approval, initial pricing would likely align with niche lipid agents, approximately $4,000-$6,000 per year per patient, comparable to PCSK9 inhibitors.
- Premium Segments: In specialized populations (e.g., statin-intolerant patients), premium pricing could reach $10,000 per year, although this depends on demonstration of clear clinical benefits.
Influencing Factors
- Regulatory Approval: Confirmatory positive trial outcomes could elevate pricing, leveraging unmet need.
- Manufacturing Costs: Technological advancements in synthesis could reduce production costs, exerting downward pressure.
- Competitive Pricing: Entry of similar agents will likely compress prices, especially as patents expire and generics/principles compete.
Future Market Projections
| Year |
Estimated Global Market Size |
Price Range (per patient/year) |
Key Assumptions |
| 2023 |
N/A (pre-market) |
N/A |
Clinical/experimental phase; no commercial sale |
| 2025 |
$500 million - $1 billion |
$5,000 - $10,000 |
Potential regulatory approval, niche adoption |
| 2030 |
$1 billion - $3 billion |
$4,000 - $8,000 |
Expanded indications, competitive pressure |
These projections assume eventual regulatory approval for specific indications and uptake within select patient populations. Market expansion hinges on safety, efficacy, and the comparative advantage over existing therapies.
Conclusion
While NDC 72205-0107 currently exists within the research and development phase with minimal commercial activity, its potential hinges on clinical outcomes and regulatory acceptance. The competitive landscape dominated by established lipid-lowering agents poses significant barriers. However, niche markets targeting unmet needs may afford opportunities for premium pricing, especially if future trials demonstrate superior efficacy or safety.
Key takeaways:
- The current clinical and market status limits near-term revenue potential.
- Avasimibe derivatives could fetch premium prices in specialized patient groups if approved.
- Competition from established lipid therapies constrains pricing power.
- Future success depends on clinical trial outcomes and regulatory pathways.
- Market expansion prospects are primarily tied to unmet needs in resistant or statin-intolerant populations.
FAQs
Q1: What is the clinical development status of NDC 72205-0107?
A1: It corresponds to avasimibe, which has largely been discontinued from early-phase trials due to safety and efficacy concerns but remains of interest in niche research settings.
Q2: Would avasimibe's price likely increase if approved?
A2: Yes. If granted regulatory approval for specific indications, especially in unmet need populations, initial pricing could be set at a premium, around $5,000-$10,000 annually.
Q3: How does the existing competitive landscape influence future prices?
A3: Established lipid-lowering agents like statins and PCSK9 inhibitors set a high competitive floor, leading to downward pressure on pricing unless avasimibe demonstrates clear superiority.
Q4: What factors could improve the market prospects for NDC 72205-0107?
A4: Positive clinical trial results, favorable regulatory decisions, breakthrough designation, or discovery of new therapeutic indications could significantly enhance market position and pricing.
Q5: What are the key risks to the market projection for this drug?
A5: Safety concerns, lack of efficacy, adverse regulatory decisions, and stiff competition from existing therapies could impede market entry or suppress price growth.
References
- [1] Clinical trial data for avasimibe, National Institutes of Health.
- [2] Pharmaceutical pricing and procurement reports, [PharmaPrice.Info], 2022.
